UK Cannabis Reform: What Is Changing and What Is Not

UK Cannabis Reform 2025: What Is Changing and What Is Not

The landscape of medical cannabis UK has evolved significantly since the initial legalisation of cannabis-based products for medical use in 2018. As we move through 2025, patients and healthcare professionals alike need clarity on what has genuinely changed, what remains static, and what this means for access to treatment. This article provides an evidence-based overview of the current status of medical cannabis in the United Kingdom.

The Current Legal Status: Clarity on What Remains Restricted

Medical cannabis remains a controlled drug under Schedule 2 of the Misuse of Drugs Regulations 2001, which means it retains its classification as a substance with recognised medical value but significant potential for harm. This fundamental legal position has not changed in 2025. Cannabis-based products for medical use (CBPMs) are only legally available through prescription from specialist clinicians—typically hospital consultants or private specialists registered with the General Medical Council.

GPs cannot prescribe cannabis-based products. This restriction remains unchanged and continues to be a significant barrier for many patients seeking access. The NHS only funds cannabis-based medications through highly specialist pathways, and even then, funding is limited and often requires extensive prior treatment with conventional therapies.

Recreational cannabis remains illegal throughout the UK. Public discourse around potential decriminalisation or broader reform has not translated into legislative change as of 2025. Possession of cannabis for personal use remains a criminal offence, with penalties ranging from warnings to prosecution depending on circumstances.

What Has Changed: Developments in Medical Access and Guidance

Since 2018, the regulatory pathway for UK cannabis law has continued to evolve, albeit gradually. The Medicines and Healthcare products Regulatory Agency (MHRA) maintains its framework for cannabis-based products, and the number of licensed products available has increased modestly. As of 2025, there are approximately three to four cannabis-based pharmaceutical products available through NHS prescribing, alongside a growing range of unlicensed products available through private practitioners.

The National Institute for Health and Care Excellence (NICE) published guidance on cannabis-based medicinal products, recommending consideration for specific conditions including refractory epilepsy, chemotherapy-induced nausea and vomiting, and multiple sclerosis spasticity. This guidance framework has been refined through 2024-2025, with ongoing review of evidence. However, NICE guidance remains advisory rather than prescriptive, and local clinical commissioning decisions continue to restrict access in many regions.

The Medical Cannabis Registry, established to collect real-world evidence on cannabis use in the UK, continues to gather data on outcomes, safety, and efficacy. This registry represents a genuine shift towards evidence generation, though recruitment and data completeness remain challenges reported across various NHS trusts.

Private prescribing has expanded modestly, with an estimated 5,000-10,000 UK patients estimated to be accessing cannabis-based products through private practitioners annually, though precise figures remain unclear due to limited centralised recording. Many of these patients pay between £150-300 per month out-of-pocket, creating significant inequity between those who can afford private access and those dependent on NHS provision.

Barriers That Persist: Unchanged Obstacles to Patient Access

Despite incremental progress, substantial barriers to access remain entrenched in 2025. NHS access is exceptionally limited, with only a small number of NHS trusts offering cannabis-based prescribing in secondary care settings. Patients in many regions have no practical route to NHS-funded treatment, regardless of clinical need. Estimated waiting times for NHS assessment, where available, range from several months to over a year in some areas.

Clinical evidence standards remain stringent. The evidence base for cannabis-based products, whilst growing, is often considered modest by conventional pharmaceutical standards. Long-term safety data, particularly for conditions beyond epilepsy and spasticity, remains limited. This conservative evidence threshold, whilst clinically cautious, excludes patients with potentially serious conditions who might benefit but fall outside NICE-recommended pathways.

Consultant resistance in many specialties persists, driven by insufficient training in cannabinoid pharmacology, concerns about dependence, and lack of familiarity with prescribing protocols. Medical cannabis remains underrepresented in undergraduate and postgraduate medical education across most UK universities.

Stigma associated with cannabis persists in healthcare settings and among the public. This continues to influence clinical decision-making and patient willingness to seek treatment through formal medical channels.

Implications for UK Patients in 2025

For patients with conditions potentially suitable for cannabis-based treatment—such as refractory epilepsy, multiple sclerosis spasticity, or neuropathic pain—the situation in 2025 remains challenging. Those with access to private specialists in major cities like London, Manchester, and Bristol may obtain treatment, albeit at significant personal cost. Patients outside these areas, or those without financial means, face practical barriers to access regardless of potential clinical benefit.

Patients seeking NHS access should be aware that their condition must align with NICE-recommended indications, prior conventional treatments must typically be exhausted, and their local NHS trust must have commissioned a cannabis service. Contacting one’s GP to enquire about local provision is a reasonable starting point, though many GPs will have limited information about regional services.

The legal distinction between medical cannabis prescribed by registered clinicians and recreational use remains absolute. Patients should not attempt to source cannabis outside the legal framework, as this exposes them to criminal liability and eliminates clinical oversight and quality control.

Looking Forward: Where Change Remains Stalled

As of 2025, there is no legislative movement towards GP prescribing rights for medical cannabis, expanded NHS commissioning, or decriminalisation of recreational use. Political appetite for further cannabis reform appears limited, with priorities focused on other healthcare pressures. Evidence generation continues gradually through the Medical Cannabis Registry and academic research, but the pace of change in policy and access remains slow.

Patients and advocates seeking expanded access should remain engaged with professional bodies such as the British Paediatric Neurology Association (for epilepsy) and charities representing specific conditions, as these organisations maintain focus on evidence and policy development.

Frequently Asked Questions

Can my GP prescribe medical cannabis in 2025?

No. GPs cannot prescribe cannabis-based products. Only specialist consultants registered with the GMC, typically in secondary care settings, can legally prescribe these medications. Access through the NHS remains extremely limited to designated specialist centres.

Is medical cannabis now covered by the NHS?

Medical cannabis may be available through specific NHS services in some regions, but coverage is highly restricted and limited to certain conditions where NICE has recommended consideration. Most patients requiring treatment must access it through private practitioners at personal cost, ranging from £150-300+ monthly.

What conditions can be treated with medical cannabis in the UK?

NICE guidance recommends considering cannabis-based products for refractory epilepsy, chemotherapy-induced nausea and vomiting, and spasticity associated with multiple sclerosis. Some private practitioners may offer treatment for other conditions, but evidence outside these indications remains limited.